NEW YORK (GenomeWeb) – CombiMatrix is developing two new tests that will expand its place in the reproductive health market, one of which will complement existing chromosomal microarray analysis services and the other of which will open CombiMatrix up to a new market segment.

The company is already benefiting from its focus on prenatal and pediatric CMA services, which drove revenues up 13 percent in the first quarter, and the firm has plans to broaden its offerings in the reproductive health arena, CEO Mark McDonough said on an earnings call.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.